Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Screening for cardiovascular disease with cholesterol.

David R Sullivan1

  • 1Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia. davids@bioc.rpa.ca.nsw.gov.au

Clinica Chimica Acta; International Journal of Clinical Chemistry
|December 1, 2001
PubMed
Summary

Screening for total cholesterol (TC) and lipoprotein levels aids in identifying individuals at high risk for cardiovascular disease (CVD). Early detection and intervention, particularly for low-density lipoprotein cholesterol (LDL-C), are crucial for preventing CVD events.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unveiling novel biomarkers for diabetes-related complications through large-scale proteomics analysis: A FIELD sub-study.

Journal of diabetes and its complications·2026
Same author

Chronic complication risk and benefits of fenofibrate in type 2 diabetes by a PPARα polymorphism (rs6008845, C/T): a FIELD trial substudy.

Diabetes research and clinical practice·2026
Same author

Corrigendum to: "Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations" [Heart Lung Circ. 32(3) (2023) 287-296.].

Heart, lung & circulation·2026
Same author

Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial.

The lancet. Diabetes & endocrinology·2025
Same author

Author reply.

Internal medicine journal·2025
Same author

Spot urine is a suitable matrix for measurement of copeptin.

Clinical chemistry and laboratory medicine·2025

Area of Science:

  • Cardiovascular Medicine
  • Clinical Chemistry
  • Public Health

Background:

  • Total cholesterol (TC) and lipoprotein measurements are key indicators for cardiovascular disease (CVD) risk.
  • Cardiovascular disorders represent a significant and growing global health burden.
  • Environmental factors like diet and exercise influence population-wide CVD risk.

Purpose of the Study:

  • To justify public health measures like screening for early identification and treatment of high-risk individuals.
  • To highlight the need for specific tests, such as lipoprotein fractions, to identify high-risk individuals.
  • To emphasize the role of interventions, especially those targeting low-density lipoprotein cholesterol (LDL-C), in CVD prevention.

Main Methods:

  • Population-wide screening using total cholesterol (TC) tests.

Related Experiment Videos

  • Specific laboratory testing of cholesterol in lipoprotein fractions for individual risk assessment.
  • Evaluation of dietary and pharmacological interventions to reduce LDL-C.

    • Main Results:

    • Simple TC tests reflect population-level risks influenced by diet.
    • Lipoprotein fraction analysis is essential for identifying individual high-risk patients.
    • Interventions reducing LDL-C are effective in preventing CVD onset or recurrence.

    Conclusions:

    • Preclinical identification of high-risk patients is desirable to prevent CVD morbidity and mortality.
    • The cost-benefit ratio of prophylactic interventions depends on accurate risk assessment via laboratory testing.
    • Balancing public health initiatives with targeted strategies for high-risk individuals is key to managing the CVD epidemic.